

MOUNJARO KWIKPEN - (10MG/2.4ML, 20MG/2.4ML, 30MG/2.4ML, 40MG/2.4ML, 50MG/2.4ML, 60MG/2.4ML ; Solution)

Generic Name	TIRZEPATIDE	Innovator	Eli Lilly
Dosage	10MG/2.4ML, 20MG/2.4ML, 30MG/2.4ML, 40MG/2.4ML, 50MG/2.4ML, 60MG/2.4ML ; Solution	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.